4//SEC Filing
Brannan Stephen K. 4
Accession 0000950170-24-029406
CIK 0001771917other
Filed
Mar 10, 8:00 PM ET
Accepted
Mar 11, 5:10 PM ET
Size
17.9 KB
Accession
0000950170-24-029406
Insider Transaction Report
Form 4
Brannan Stephen K.
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2024-03-08$5.45/sh+2,500$13,625→ 42,604 total - Exercise/Conversion
Common Stock
2024-03-08$111.97/sh+1,791$200,538→ 47,604 total - Exercise/Conversion
Option (right to buy)
2024-03-08−2,500→ 4,677 totalExercise: $5.45Exp: 2027-06-01→ Common Stock (2,500 underlying) - Sale
Common Stock
2024-03-08$318.33/sh−4,900$1,559,817→ 42,704 total - Sale
Common Stock
2024-03-08$318.96/sh−100$31,896→ 42,604 total - Exercise/Conversion
Option (right to buy)
2024-03-08−3,209→ 12,837 totalExercise: $131.64Exp: 2031-02-22→ Common Stock (3,209 underlying) - Exercise/Conversion
Option (right to buy)
2024-03-08−1,791→ 37,813 totalExercise: $111.97Exp: 2032-02-16→ Common Stock (1,791 underlying) - Exercise/Conversion
Common Stock
2024-03-08$131.64/sh+3,209$422,433→ 45,813 total
Footnotes (5)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2023.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $317.94 to $318.93, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of March 1, 2017, with additional vesting as to 12.5% of the shares underlying the option award at the end of each six month period thereafter.
- [F4]This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of February 23, 2021, with additional vesting as to 6.25% of the shares underlying the option award at the end of each three month period thereafter.
- [F5]This option vested as to 25% of the shares on the first anniversary of the vesting commencement date of February 16, 2022, with additional vesting as to 6.25% of the shares underlying the option award at the end of each three month period thereafter.
Documents
Issuer
Karuna Therapeutics, Inc.
CIK 0001771917
Entity typeother
Related Parties
1- filerCIK 0001777631
Filing Metadata
- Form type
- 4
- Filed
- Mar 10, 8:00 PM ET
- Accepted
- Mar 11, 5:10 PM ET
- Size
- 17.9 KB